News | August 04, 2011

Study: Positron Emission Mammography (PEM) May Help Predict Breast Cancer Survival

August 4, 2011 – Published last week in The American Journal of Roentgenology, researchers from Swedish Cancer Institute and the University of Washington used positron emission mammography (PEM) to find a correlation between fludeoxyglucose (FDG) uptake values and the prognostic factors that predict breast cancer survival. The highest FDG levels were in the most aggressive cancer type – triple negative cancers. Women with triple negative breast cancer have a higher mortality because there is no tailored therapy available to them. PEM may now benefit this patient population as it may help identify when a chemotherapeutic regimen is not working. PEM also has the potential to play a role in initial staging of breast cancer in patients at high risk for multifocal or multicentric disease who desire breast conservation therapy as an alternative to breast MRI.

PEM is the breast application of the Naviscan high-resolution PET scanner showing the location as well as the metabolic phase of a lesion. It is the only U.S Food and Drug Administration (FDA)-cleared 3-D molecular breast imaging (MBI) device on the market. The metabolic view assists physicians in making optimal care decisions by providing an ability to distinguish between benign and malignant lesions, what researchers term "specificity."

Histologic grade, tumor size and expression of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu receptor are considered important prognostic variables in the clinical management of breast cancer. According to the publication authors, this is the first study to evaluate the correlation between prognostic indicators and FDG uptake values on PEM.

"PEM shows a significant positive correlation between FDG uptake and various prognostic factors since the advent of hormonal therapy such as hormone receptor status and histologic grade," stated Carolyn Wang, M.D., the lead author of the paper. "Lesion to background (LTB) may be a reflection of associated high-risk markers to be determined, and developing a sensitive imaging strategy for small tumors to complement immunohistochemical markers ER, PR, and HER2 may provide additional prognostic information at the molecular level. Further prospective studies will be needed to assess whether PEM FDG uptake is validated as an independent marker. This may affect treatment options and may be a marker to evaluate response to specific therapy."

PEM images from 98 newly diagnosed breast cancer patients with 100 lesions were reviewed by two physicians blinded to pathology results. Tumor FDG uptake and lesion to background (LTB) ratio levels were compared to ER, PR and HER2 receptor status. Results showed that high LTB ratio correlated with receptor status for ER-neg and PR-neg and that triple negative tumors had a higher LTB ratio. Breast tumors with higher histologic grade also had significantly higher FDG uptake than those with lower grade.

For more information: www.naviscan.com

 

Related Content

Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

News | Mammography | June 14, 2019
Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused...
Ikonopedia Showcases Risk Assessment and Resolution Manager Tools at SIIM and AHRA
News | Mammography Reporting Software | June 13, 2019
Ikonopedia will showcase its suite of structured breast reporting and Mammography Quality Standards Act (MQSA)...
Sponsored Content | Videos | Radiology Imaging | June 13, 2019
In an interview with itnTV, Henry Izawa, vice president, modality solutions and clinical affairs, Fujifilm Medical Sy
iCAD Introduces ProFound AI for 2D Mammography in Europe
News | Artificial Intelligence | June 13, 2019
iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to...
Three Palm Software Releases WorkstationOne Version 1.8.8
Technology | Mammography Reporting Software | June 12, 2019
Three Palm Software announced the release of the 1.8.8 version of its breast imaging workstation, WorkstationOne. This...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
Volpara Health Technologies to Acquire MRS Systems Inc.
News | Mammography Reporting Software | June 04, 2019
Volpara Health Technologies, Volpara Solutions' parent company, has signed a binding agreement to acquire U.S.-based...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
AI Biomarker Demonstrates High Predictive Power for Lung Cancer Immunotherapy
News | Artificial Intelligence | May 31, 2019
Lunit announced an abstract presentation of its artificial intelligence (AI) precision medicine research portfolio at...